Navigation Links
Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
Date:12/13/2007

OXFORD, England, Dec. 13 /PRNewswire/ -- Chroma Therapeutics Limited, one of the UK's leading pre-IPO biotechnology companies, announced today positive data from a Phase I study with its oral, once-daily experimental cancer therapy CHR-2797 in the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and multiple myeloma (MM) who have failed on, or who are unsuitable for, chemotherapy.

Headline data from the study, which was presented by a key study investigator, Dr. Faith Davies of the Royal Marsden Hospital, London, were as follows:

-- 3 out of 13 AML patients treated in this study showed a complete

response (CR) and one further AML patient became

transfusion-independent;

-- one MM patient (out of two treated in this study) remained in stable

disease after six months of treatment with CHR-2797; and

-- the drug was very well-tolerated during the study

Chroma is currently assessing CHR-2797 in AML and MDS patients in the Phase II portion of this trial. This trial is now fully recruited and results are expected in the first half of 2008.

Ian Nicholson, Chief Executive Officer of Chroma, commented: "We are very encouraged by the efficacy we have seen in this Phase I study and look forward to further exploring how patients with this debilitating disease might be treated with CHR-2797".

An abstract of the data from this study was submitted to the recent American Society of Hematology (ASH) meeting and was subsequently selected for oral presentation. The full ASH presentation will be available at the company's website, http://www.chromatherapeutics.com.

Enquiries

Chroma Therapeutics Limited

Ian Nicholson Chief Executive Officer +44 (0)1235 829120

Richard Bungay Chief Financial Officer

Brunswick

Jon Coles
'/>"/>

SOURCE Chroma Therapeutics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Pharmaceutical and biotech marketers are ... for the same indication. This can be a complex ... prevent one of their brands from gaining market share ... recent research by benchmarking firm, Best Practices, LLC, 75% ... rather than together as part of a franchise. Marketers ...
(Date:2/27/2015)... 2015  Acsis Inc., the market leader for supply ... that John DiPalo , Acsis, Chief Strategy Officer, ... Chain Executive 2015 Provider Pro to Know. The ... to help prepare their companies, and customers, supply chains ... year,s list of Provider Pros to Know is featured ...
(Date:2/27/2015)... TX , Feb. 27, 2015 /PRNewswire/ - ESSA Pharma ... Burton & Co. Ltd. ("Bloom Burton") today announced that ... 2,353,130 common shares of the Company ("Common Shares") representing ... Lock-Up. Of the Common Shares released from the Lock-Up, ... from the Lock-Up while the remainder will be subject ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as part ... the latest and coolest technology products and services available to ... technology expert, conducted the review and shared with viewers how ... stuck with a low battery and no way to charge ... on a daily basis. Even when a person does have ...
(Date:2/28/2015)... Memphis, TN: MedixSafe has retracted a previous announcement ... reader named Guardian 2. The correct product name ... scanner that significantly increases the complexity of security ... scanner provides fast and easy access for both ... lockers with Vanguard technology tracks inventory by ...
(Date:2/28/2015)... 28, 2015 My Shiney Hiney® LLC., the ... team to Las Vegas, Nevada for the annual ASD Market ... of the leading consumer-goods tradeshows and My Shiney Hiney will ... event. My Shiney Hiney can be found at booth number ... for the at-home personal hygiene brush and cleansing system exclusively ...
(Date:2/27/2015)... 27, 2015 Hispanics develop alcoholic liver ... four and 12 years earlier than Whites/Caucasians or African ... Health System. , While previous research indicated that Hispanics ... the new study -- published online in the journal ... be the first to pinpoint racial and ethnic disparities ...
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
Breaking Medicine News(10 mins):Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:UC Davis Study Finds Hispanics Develop Alcoholic Liver Disease at Younger Ages than Caucasians or African Americans 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... time , , TUESDAY, Jan. 15 (HealthDay News) -- Foodborne illness can ... different pathogens. Here is a rundown of the most common bacterial ... E. COLI 0157:H7 , There are many strains ... coli. Most are harmless, four or five can cause disease, and ...
... drinks containing live bacteria, have a tangible effect on the ... today (Tuesday 15 January) in the journal Molecular Systems Biology. ... at how probiotics change the biochemistry of bugs known as ... an important part in a persons metabolic makeup. Different people ...
... Integrated Solutions Help Dearborn County Hospital Better Serve ... Area with Heightened Productivity and Collaboration, ... Dearborn County Hospital,in southeast Indiana, efficient yet responsive ... patients and patient,families. To boost care levels even ...
... Postmenopausal women who take combined estrogen/progestin hormone-replacement ... fourfold increased risk of developing various forms of ... researchers at Fred Hutchinson Cancer Research Center., Previous ... combined hormone-therapy use was necessary to increase overall ...
... feedback feature promotes a more informed health care ... and regional studies,indicate that informed patients make better ... is launching a member feedback feature in,Spring 2008 ... to share,information with each other about their provider ...
... Rivers,Pharmaceuticals, LLC finalized acquisition of the hepatitis C ... ). Valeant is,receiving $91 million from Three Rivers ... growing portfolio is very exciting," said,Donald J. Kerrish, ... purchase is only a beginning for Three Rivers, ...
Cached Medicine News:Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 2Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 3Health News:U.S. Food Safety: Foodborne Illnesses a Menu for Disaster 4Health News:Probiotics affect metabolism, says new study 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 2Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 3Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 4Health News:Tri-State Hospital to Gain Greater Efficiency and Responsiveness in Delivering Patient Care with Siemens Open Communications Solutions 5Health News:Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use 2Health News:Regence Enables Members to Share Feedback With Each Other When Researching Health Care Provider Options 2Health News:Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals 2
Inquiry 4Fr, 5Fr and 6Fr diagnostic electrophysiology catheters offer simple, precise distal control with it's patented Easy-Hand steering mechanism....
... offers patient monitoring products for hospital ... medium acuity monitoring. The Envoy patient ... The Enmove monitor offers a ... complement the Envoy. The Ensemble ...
... The Mayfield Triad Skull Clamp, compatible with ... visual indication of clamping force on all ... user with the possibility of adjusting the ... can easily be increased or decreased by ...
Protein-to-creatinine ratio is key to earlier detection of Kidney Disease...
Medicine Products: